Join
Live feed
·
PRReleasevia Quantisnow
Atara Biotherapeutics Inc. logo

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

ByQuantisnow·Wall Street's wire, on your screen.
ATRA· Atara Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATRA (Atara Biotherapeutics Inc.) and more on Quantisnow.